# Merck & Co. (MRK) 8-K SEC filing

- Filed: Apr 30, 2026, 6:53 AM EDT
- Accession: 0001104659-26-052081
- OpenCapital page: https://www.opencapital.sh/filings/0001104659-26-052081
- Markdown URL: https://www.opencapital.sh/filings/0001104659-26-052081.md
- Official SEC filing index: https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/0001104659-26-052081-index.htm

## Filing documents

- [8-K (tm2612241d1_8k.htm)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_8k.htm)

---

## 8-K

SEC source: [tm2612241d1_8k.htm](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_8k.htm)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**

**The Securities Exchange Act of 1934**

Date of Report (Date of earliest event
reported)  **April 30, 2026 (April 30, 2026****)**

**Merck & Co., Inc.**

(Exact name of registrant as specified in
its charter)

**New Jersey**<br>(State or other jurisdiction<br>of incorporation) **1-6571**<br>(Commission<br>File Number) **22-1918501**<br>(I.R.S. Employer<br>Identification No.)

**126 East Lincoln Avenue, Rahway, NJ**<br>(Address of principal executive offices) **07065**<br>(Zip Code)

Registrant’s telephone number, including area code **(908) 740-4000**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class / Common Stock ($0.50 par value) | Trading Symbol(s) / MRK | Name of each exchange on which registered / New York Stock Exchange |
| --- | --- | --- |
| 1.875% Notes due 2026 | MRK/26 | New York Stock Exchange |
| 3.250% Notes due 2032 | MRK/32 | New York Stock Exchange |
| 2.500% Notes due 2034 | MRK/34 | New York Stock Exchange |
| 1.375% Notes due 2036 | MRK 36A | New York Stock Exchange |
| 3.500% Notes due 2037 | MRK/37 | New York Stock Exchange |
| 3.700% Notes due 2044 | MRK/44 | New York Stock Exchange |
| 3.750% Notes due 2054 | MRK/54 | New York Stock Exchange |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

**Item
2.02. Results of Operations and Financial Condition****.**

The following information, including the exhibits hereto,
is being furnished pursuant to this Item 2.02.

Incorporated by reference is a
press release issued by Merck & Co., Inc. on April 30, 2026, regarding earnings for the first quarter of 2026, attached as Exhibit
99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

## Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits

[Exhibit 99.1](tm2612241d1_ex99-1.htm) [Press release issued April 30, 2026, regarding earnings for the first quarter of 2026](tm2612241d1_ex99-1.htm)

[Exhibit 99.2](tm2612241d1_ex99-2.htm) [Certain supplemental information not included in the press release](tm2612241d1_ex99-2.htm)

Exhibit 104 Cover  Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Merck  & Co., Inc.

Date:  April 30, 2026 By: /s/  Kelly E. W. Grez

Kelly E. W. Grez

Corporate Secretary